Group 1: Control Change Announcements - Multiple A-share companies, including Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced plans for control changes on September 28 [1][3][4] - Duori Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., is planning a control change, leading to a potential change in the actual controller [1] - Asia-Pacific Pharmaceutical's controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., is also planning a control change, with no formal agreement signed yet [3] - Zhonghuan Environmental Protection's controlling shareholder, Zhang Bozhong, is in the process of planning a control change, which may affect the actual controller [4] Group 2: Company Profiles and Operations - Duori Pharmaceutical specializes in the R&D, production, and sales of chemical drug formulations and intermediates, with leading market share in products like Acetate Sodium Ringer Injection [1] - Asia-Pacific Pharmaceutical focuses on pharmaceutical manufacturing, including the R&D and sales of chemical formulations, with a portfolio of 114 approved formulations [3] - Zhonghuan Environmental Protection is a national high-tech enterprise engaged in water environment governance and waste treatment, providing comprehensive solutions in various segments [5] - Guanzhong Ecology is undergoing a control change with a share transfer agreement to Deep Blue Whale, which will result in a new controlling shareholder [7]

亚太药业（002370）(002370.SZ)公告，公司于2025年9月26日收到控股股东宁波富邦（600768）控股集 团有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团 队及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一 步论证和磋商，目前相关各方尚未签署正式交易协议。公司股票自2025年9月29日开市起停牌，预计停 牌时间不超过2个交易日。 ...

智通财经APP讯，亚太药业(002370.SZ)公告，公司于2025年9月26日收到控股股东宁波富邦控股集团有 限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及 一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步论 证和磋商，目前相关各方尚未签署正式交易协议。公司股票自2025年9月29日开市起停牌，预计停牌时 间不超过2个交易日。 ...

亚太药业表示，上述事项可能导致公司控股股东及实际控制人发生变更。鉴于上述事项处于筹划阶段， 尚存在重大不确定性，为保证公平信息披露，避免公司股价异常波动， 维护广大投资者利益，经公司 向深交所申请，公司股票自9月29日开市起停牌，预计停牌时间不超2个交易日。 北京商报讯（记者 丁宁）9月28日晚间，亚太药业（002370）发布公告称，公司于9月26日收到控股股 东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡 铮辉组成的管理团队及一致行动人宋凌杰的通知， 其正在筹划公司控制权变更事项，具体交易方案、 协议条款等尚需进一步论证和磋商，目前相关各方尚未签署正式交易协议。具体情况届时以各方签订的 相关正式交易协议为准。 ...

Group 1 - The core point of the article is that Asia Pacific Pharmaceutical (SZ 002370) announced a potential change in control, with its major shareholder, Ningbo Fubang Holding Group, and associated parties planning to negotiate the terms of the transaction [1] - The company has applied for a trading suspension starting September 29, 2025, to prevent abnormal stock price fluctuations during this uncertain period [1] - For the first half of 2025, the company's revenue composition shows that the pharmaceutical manufacturing sector accounted for 99.33% of total revenue, while other businesses contributed 0.67% [1] Group 2 - As of the report, Asia Pacific Pharmaceutical has a market capitalization of 4.2 billion yuan [2]

格隆汇9月28日丨亚太药业(002370.SZ)公布，收到控股股东宁波富邦控股集团有限公司及一致行动人上 海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及一致行动人宋凌杰的通 知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步论证和磋商，目前相关各 方尚未签署正式交易协议。具体情况届时以各方签订的相关正式交易协议为准。经公司向深圳证券交易 所申请，公司股票自2025年9月29日（星期一）开市起停牌，预计停牌时间不超过2个交易日。 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-069 浙江亚太药业股份有限公司 关于筹划公司控制权变更事项的停牌公告 本公司及董事会全体成员保证信息披露内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、公司股票自 2025 年 9 月 29 日开市起停牌，预计停牌时间不 超过 2 个交易日。 2、公司控制权变更事项目前处于筹划阶段，尚存在重大不确定 性，敬请广大投资者注意投资风险。 浙江亚太药业股份有限公司（以下简称"公司"）于 2025 年 9 月 26 日收到控股股东宁波富邦控股集团有限公司及一致行动人上海 汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管 理团队及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项， 具体交易方案、协议条款等尚需进一步论证和磋商，目前相关各方尚 未签署正式交易协议。具体情况届时以各方签订的相关正式交易协议 为准。 停牌期间，公司将根据相关事项进展情况，严格按照相关法律法 规的规定和要求履行信息披露义务，待上述事项确定后，公司将及时 发布相关公告并申请公司股票复牌。 公 司 指 定 信 息 披 露 媒 体 为 《 ...

资料显示，浙江亚太药业股份有限公司位于浙江省绍兴滨海新城沥海镇南滨西路36号，成立日期2001年 12月31日，上市日期2010年3月16日，公司主营业务涉及医药制造业务,包括化学制剂、化学原料药的研 发、生产和销售。主营业务收入构成为：抗生素类制剂56.49%，非抗生素类制剂42.84%，其他(补 充)0.67%。 截至6月30日，亚太药业股东户数5.51万，较上期减少9.36%；人均流通股13532股，较上期增加 11.23%。2025年1月-6月，亚太药业实现营业收入1.52亿元，同比减少31.48%；归母净利润1.05亿元，同 比增长1820.97%。 9月17日，亚太药业跌2.41%，成交额2.56亿元。两融数据显示，当日亚太药业获融资买入额1585.92万 元，融资偿还2059.13万元，融资净买入-473.21万元。截至9月17日，亚太药业融资融券余额合计1.89亿 元。 融资方面，亚太药业当日融资买入1585.92万元。当前融资余额1.89亿元，占流通市值的4.17%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，亚太药业9月17日融券偿还0.00股，融券卖出0.00股，按当日收盘 ...

Core Points - Asia-Pacific Pharmaceutical experienced a decline of 6.39% in stock price, with a turnover rate of 15.74% and a trading volume of 757 million yuan, indicating significant market activity [2] - Institutional investors net sold 50.94 million yuan, while brokerage seats collectively net bought 1.36 million yuan, reflecting a bearish sentiment among institutional players [2] - The stock was listed on the Shenzhen Stock Exchange's watchlist due to a price deviation of -9.58%, highlighting volatility in its trading [2] Trading Data - The top five brokerage seats accounted for a total trading volume of 138 million yuan, with a buying amount of 44.25 million yuan and a selling amount of 93.83 million yuan, resulting in a net sell of 49.58 million yuan [2] - Among the brokerage seats, four institutional specialized seats were involved in selling, with a total buying amount of 4.99 million yuan and a selling amount of 55.93 million yuan, leading to a net sell of 50.94 million yuan [2] Fund Flow - The stock saw a net outflow of 61.92 million yuan in main funds today, with a significant outflow of 40.85 million yuan from large orders and 21.07 million yuan from major funds [2] - Over the past five days, the main funds experienced a net inflow of 72.19 million yuan, indicating a potential recovery trend [2]

Core Viewpoint - The recent financial report of Asia-Pacific Pharmaceutical (002370) shows a significant decline in total revenue but a remarkable increase in net profit, indicating a complex financial situation with rising costs impacting overall performance [1]. Financial Performance - Total revenue for the first half of 2025 was 152 million yuan, a decrease of 31.48% year-on-year [1]. - Net profit attributable to shareholders reached 105 million yuan, an increase of 1820.97% year-on-year [1]. - In Q2 2025, total revenue was 87.52 million yuan, down 19.86% year-on-year, while net profit was 113 million yuan, up 1233.32% year-on-year [1]. - Gross margin was 31.66%, a slight decrease of 0.58% year-on-year, while net margin surged to 69.16%, an increase of 2703.45% year-on-year [1]. Cost Structure - The combined expenses (selling, administrative, and financial) accounted for 55.54% of total revenue, an increase of 84.8% year-on-year, totaling 84.46 million yuan [1]. - The company’s financial expenses relative to operating cash flow have reached 115.46% over the past three years, indicating potential concerns regarding financial management [3]. Asset Management - Cash assets remain healthy, with cash and cash equivalents reported at 625 million yuan, down 8.91% year-on-year [1][2]. - Accounts receivable increased by 29.81% year-on-year, reaching 96.91 million yuan, which raises concerns as it represents 283.04% of profit [3]. Shareholder Metrics - Earnings per share (EPS) increased to 0.14 yuan, a rise of 1300.00% year-on-year [1]. - Book value per share rose to 1.51 yuan, an increase of 106.1% year-on-year [1]. - Operating cash flow per share decreased to 0.04 yuan, down 29.66% year-on-year [1]. Business Model and Market Position - The company’s performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors influencing this drive [2]. - Historical data indicates a weak return on invested capital (ROIC) of 4.16% last year, with a median ROIC of 4.38% over the past decade, suggesting challenges in capital efficiency [1].